Business Expanding Arcturus Therapeutics, a U.S. developer of mRNブラック ジャック ブラック クイーンedicines, has established a Japanese subsidiary in Chiba Prefecture as a joint venture with Axcelead, Inc., and is setting up ブラック ジャック ブラック クイーンanufacturing plant in Minamisoma City, Fukushima Prefecture

Arcturus’ lipid nanoparticle (LNP) technology is called LUNAR®. The company’s core technologies include designing and manufacturing of RNA nucleic acid-based therapeutic candidates (including mRNA, siRNA, and miRNA) and a drug delivery system that uses its proprietary lipids. LUNAR® carries the messenger RNA (mRNA) which is a copy of the base sequence from DNA and express proteins of a protective or therapeutic value, and delivery technology for administration of the mRNA that can make proteins in the body. Arcturus has partnered research programs with Janssen Pharmaceuticals, ブラック ジャック ブラック クイーンember of Johnson & Johnson group in the U.S., Takeda Pharmaceutical Company Limited, and other pharmaceutical companies. In response to the spread of COVID-19, the company has begun developing an mRNA vaccine for COVID-19 and is currently conducting clinical trials in the U.S., Singapore and Vietnam.

In April 2021, Arcturus ブラック ジャック ブラック クイーンxcelead entered into the joint venture, ARCALIS, Inc., and set up a base in Kashiwa City, Chiba Prefecture. Then, in May of the same year, ブラック ジャック ブラック クイーンompany announced its plans to establish a plant in Minamisoma City, Fukushima Prefecture, and build facilities to produce next-generation mRNA vaccines, including for COVID-19 by 2025.

ARCALIS, Inc. is the first company in Japan to develop its business as a contract development and manufacturing organization (CDMO), specializing in mRNブラック ジャック ブラック クイーンedicines. While serving as ブラック ジャック ブラック クイーンanufacturing base for Arcturus Therapeutics’ R&D, clinical, and commercial pipelines, the company plans to develop the world's first integrated business as CDMO of mRNブラック ジャック ブラック クイーンedicines, which provides a stable supply of high-quality mRNブラック ジャック ブラック クイーンedicines to a wide range of customers, including pharmaceutical companies, drug discovery ventures, and academia around the world, by conducting integrated operations from the development of manufacturing and analytical methods to the production of active pharmaceutical ingredients and formulation of them into ブラック ジャック ブラック クイーンedicine. By acquiring the license of mRNA production technology from Arcturus Therapeutics, the company aims to start manufacturing and supplying pharmaceuticals that meet cGMP standards (Note) within 2023.